ArticleApplied biochemistry and biotechnology2026
Erythropoietin and Ferulic Acid Loaded on Fe
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute kidney damage occurs in 30%–46% of patients receiving cisplatin chemotherapy; nevertheless, effective preventive and treatment strategies are insufficient. Ferulic acid, despite its potent antioxidant and anti-inflammatory properties, exhibits from poor aqueous solubility, rapid metabolism, and low bioavailability, which significantly limit its therapeutic efficiency in vivo when administered in its free form. Therefore, an effective delivery system was required to overcome these limitations, enhance FA stability, and prolong its biological residence time in renal tissue. Fe₃O₄ nanoparticles provided an appropriate solution to this challenge by coating it to a core-shell system of Fe₃O₄@C nanoparticles, which were selected not only as a carrier but also to enhance FA delivery, maintaining its therapeutic activity, and providing superior nephroprotection. Objectives: The present research demonstrates the therapeutic efficacy of Erythropoietin (EPO), magnetic nanoparticles (Fe3O4-NPs), Ferulic acid (FA), and FA-loaded Fe3O4-NPs@C against AKI induced by cisplatin. Methods: Forty-two rats were divided into seven groups (n = 6). Normal control, cisplatin (6 mg/kg), cisplatin + EPO (1000 IU/kg, intraperitoneally), cisplatin + FA (50 mg/kg, orally), cisplatin + Fe3O4-NPs (5 mg/kg, intraperitoneally), combination group (cisplatin, EPO, FA, and Fe3O4-NPs), and cisplatin + FA/Fe3O4-NPs@C (5 mg/kg, intraperitoneally). Euthanisation occurred after 7 days of administration. Results: Cisplatin-induced nephrotoxicity significantly elevated renal markers compared to the normal group (p ≤ 0.05), with creatinine reaching 0.93 mg/dL and urea 116.88 mg/dL. Treatment with ferulic acid (FA), Fe3O4-NPs, and erythropoietin (EPO) reduced these levels. At the same time, their combination and FA/Fe3O4-NPs@C further significantly decreased creatinine and urea levels (p ≤ 0.05), thereby restoring renal function and elevating antioxidants (catalase, glutathione reductase, superoxide dismutase). Notably, GPX-4 levels markedly increased (p ≤ 0.05) in the FA/Fe3O4-NPs@C group, confirming ferroptosis inhibition via upregulated ferritin and GSH; Bcl-2 expression rose while Bax declined (p ≤ 0.05), indicating anti-apoptotic effects. These biochemical changes were corroborated by histopathological and immunohistochemical findings, with reduced inflammation (downregulated IL-6) and fibrosis (downregulated TGF-β). Conclusion: FA/Fe3O4-NPs@C protects against nephrotoxicity of cisplatin by restoring renal antioxidant defenses, inhibiting inflammation, ferroptosis, and apoptosis, thereby enhancing renal function and recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.